14 completed. 14 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 2 | 5 | Completed 5 |
Follow ADHD: new trials by email Literature Review of ADHD trials Research Report on ADHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| Biomarkers of ADHD Treatment Response Concerta, Adderall-XR - ADHD | Phase 1 | Completed | Boston Children's Hospital | 16 | 2023-02-17 | 2024-12-18 |
| Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo - ADHD, Narcolepsy | Phase 1 | Completed | Vallon Pharmaceuticals, Inc. | 55 | 2020-10-05 | 2021-12-29 |
| CTx-1301 Comparative Bioavailability Study Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release - ADHD | Phase 1 / Phase 2 | Completed | Cingulate Therapeutics | 45 | 2019-12-06 | 2021-04-08 |
| Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR) ADAIR 10mg IR capsules, Crushed d-amphetamine sulfate IR tablets - ADHD, Narcolepsy | Phase 1 | Completed | Vallon Pharmaceuticals, Inc. | 16 | 2019-05-27 | 2020-01-18 |
| Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Brexpiprazole - ADHD, Autism | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2017-10-10 | 2018-06-12 |
| Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD Magnetic Resonance Imaging (MRI), PHNO, calcitriol - ADHD | Phase 1 | Completed | Yale University | 24 | 2017-08-15 | 2024-03-19 |
| TD-9855 Mass Balance Study TD-9855 - ADHD, Fibromyalgia | Phase 1 | Completed | Theravance Biopharma | 6 | 2013-10-01 | 2021-01-19 |
| Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD) V81444, Placebo - ADHD | Phase 1 / Phase 2 | Completed | Vernalis (R&D) Ltd | 31 | 2013-07-01 | 2016-06-03 |
| Nicotine, Non-Smokers With and Without ADHD, and Genetics Study Nicotine nasal spray, Placebo - Non-smoker, ADHD | Phase 1 | Completed | Scott Kollins, PhD | 136 | 2013-01-01 | 2018-11-30 |
| SPD544 High Strength Bioequivalence Study SPD544, Methylphenidate hydrochloride - ADHD | Phase 1 | Completed | Shire | 28 | 2010-08-27 | 2021-06-09 |
| My Scrivener® - Measuring Effectiveness and Dose Response in Children My Scrivener(R) - Asperger's Syndrome, Dyslexia | Phase 1 / Phase 2 | Completed | Obslap Research LLC | 176 | 2009-04-01 | 2010-10-28 |
| Supplementation of Polyunsaturated Fatty Acids in Children With Attention Deficit/Hyperactivity Disorder (ADHD) Eye Q - ADHD | Phase 1 / Phase 2 | Completed | Medical University of Warsaw | 89 | 2007-01-01 | 2014-04-15 |
| The Reinforcing Mechanisms of Smoking in Adult ADHD ADHD medication, Placebo - ADHD | Phase 1 / Phase 2 | Completed | University of California, Irvine | 27 | 2006-09-01 | 2011-11-07 |
Attention Deficit Disorder with Hyperactivity (14) · Narcolepsy (2) · Asperger Syndrome (1) · Autistic Disorder (1) · Brain Injuries, Traumatic (1) · Central Nervous System Diseases (1) · Cerebral Palsy (1) · Conduct Disorder (1) · Dyslexia (1) · Fibromyalgia (1) · Oppositional Defiant Disorder (1) · Smoking (1) · Stroke (1)
Attention Deficit and Disruptive Behavior Disorders (14) · Mental Disorders (14) · Neurodevelopmental Disorders (14) · Nervous System Diseases (5) · Autism Spectrum Disorder (2) · Child Development Disorders, Pervasive (2) · Disorders of Excessive Somnolence (2) · Dyssomnias (2) · Sleep Disorders, Intrinsic (2) · Sleep Wake Disorders (2) · Behavior (1) · Brain Damage, Chronic (1) · Brain Diseases (1) · Brain Injuries (1) · Cardiovascular Diseases (1)
Dextroamphetamine (3) · Methylphenidate (3) · Lisdexamfetamine Dimesylate (2) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (1) · Atomoxetine Hydrochloride (1) · Calcitriol (1) · Capsules (1) · Dexmethylphenidate Hydrochloride (1) · Magnetic Resonance Spectroscopy (1) · SLI381 (1) · Tablets (1) · Tobacco Use Cessation Devices (1) · ampreloxetine (1) · brexpiprazole (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Vallon Pharmaceuticals, Inc. (2) · Boston Children's Hospital (1) · Cingulate Therapeutics (1) · Medical University of Warsaw (1) · Obslap Research LLC (1) · Scott Kollins, PhD (1) · Shire (1) · Theravance Biopharma (1) · University of California, Irvine (1) · Vernalis (R&D) Ltd (1) · Yale University (1)
United States (11) · Canada (1) · Poland (1) · United Kingdom (1)
Anne B Arnett, PhD (1) · Bradley Vince, MD (1) · Eugenia Chan, MD (1) · Jean G Gehricke, Ph.D. (1) · Magdalena Grygo, MD (1) · Marc Potenza, PhD, MD (1) · Matt Brams, MD (1) · Scott H Kollins, Ph.D. (1) · Susan E Palsbo, PhD (1) · Timothy Whitaker, M (1) · Timothy Whitaker, MD (1)
PMID 21356232, PMID 23106988, PMID 37058600, PMID 42518155
R01AT010508 (1), R01DA033080 (1)